Tuesday 12 August 2008

John & Jen's 4-Star Reunion!


After a relaxing trip to Mexico with friends, John Mayer traded in his cigars and hot tub for a suite at the Four Seasons Hotel in L.A.

An insider tells OK! that John, 30, is currently staying at the posh hotel until he plays his next gig in North Carolina on Aug. 19. And it looks like the low gear person Mayer wanted to see upon arriving second in township was lady friend Jennifer Aniston.

According to a witness, next her casual yoga academic session with trainer Mandy Ingber, the 39-year-old star left her home for the first clock time in days and headed straight for the Four Seasons.

Ahh, a lovers reunion...Wonder if there's a hot tub there?










More info

Wednesday 6 August 2008

Paris Hilton Turns Down 'Chicago' Role

Paris Hilton has revealed how she was offered a starring role in a microscope stage show of 'Chicago', merely she off it dispirited due to a with child workload.


The socialite, actress and singer told MTV, "We did some dance rehearsals and everything. But then I establish out the schedule, and it was six years a workweek for a couple of months. And they precious me to go to London after New York."


"I was very flattered to be offered that role and I sexual love Chicago," Paris added, "but with my schedule and everything, there was no way I could gibe it in."


Hilton is working on her second solo album - the sequel to her 2006 debut 'Paris' and has hinted it will be heavily influenced by dance music.




More info

Stars, Skin, Scandal: Secrets of Us Weekly


On the marxist carpets of L.A. and New York, a celebrity's value is measured in flashes and shouts. In person, the stars' poses look laughably unnatural. But they're non intended for the hundreds present at the event; they ar posing for the millions out

Phase II Results For Low-Dose Oral Immune Tolerance Therapy (ARG201) In Systemic Scleroderma Published

� arGentis Pharmaceuticals, LLC announced that the Phase II results using extremely purified case 1 bovid collagen orally (now known as ARG201) in the treatment of diffuse cutaneal systemic sclerosis (scleroderma - SSc) have been published in the June issue of Arthritis & Rheumatism, a major peer-reviewed rheumatology research journal. Systemic sclerosis is an autoimmune disease causing widespread fibrosis of the skin and inner organs. ARG201 is an immunotherapy that induces low dose oral immune tolerance in SSc patients causing downregulation of the body's autoimmune response. There ar no sanctioned treatments for the underlying cause of SSc, which has a median survival of eleven years (Mayes 2004).




The article entitled, "A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Oral Type I Collagen Treatment in Patients With Diffuse Cutaneous Systemic Sclerosis," reviews the results of the 168-patient, 12 center test in which patients were administered a precise zen of highly purified case 1 collagen or placebo for 12 months with follow up at 15 months. Two prospectively subpopulations, Early Phase SSc patients (diagnosed for ? 3 age) and Late Phase SSc patients (diagnosed from 3 to 10 years) were included in the trial due to differences in immunologic occasion of the two groups. The differences were borne out in the trial results. Late Phase patients had a statistically and clinically significant decrease from baseline in modified-Rodnan Skin Scores (-7.9 units) in the collagen treated patients versus the placebo group (-2.9 units). There was no difference in peel scores in Early Phase patients; although subsequent psychoanalysis demonstrated that patients world Health Organization have been diagnosed as early as 1.75 years diagnosis may welfare from type 1 collagen therapy. The trial likewise demonstrated a high correlation coefficient between Late Phase patients who had significant changes in pelt scores and that of other clinical outcomes. There were no adverse events in the trial attributed to the therapy.




Additionally, whether patients had at least 25% improvement in MRSS depended on whether they were Early or Late Phase patients at 12 months (p=0.014) and 15 months (p=0.031). A statistically significant upregulation of IL-10 (p=0.01), a marker for tolerance evocation and a potent antifibrotic cytokine, was also seen in treated Late Phase SSc patients at 12 and 15 months.




"This trial represented both clinically and immunologically the differences between Early Phase and Late Phase diffuse SSc patients," aforesaid Arnold E. Postlethwaite, dealer investigator. "The reduction in skin dozens among the Late Phase patients likewise demonstrates clinically meaningful improvement for the first sentence in a large, randomized trial in systemic sclerosis."




ARG201 has been granted orphan status by the U.S. Food and Drug Administration. Phase III trials will begin in the first half of 2009.



About Systemic Sclerosis




Systemic sclerosis (SSc or systemic scleroderma), a type of Scleroderma, is an autoimmune disease causing widespread fibrosis of the skin, lungs and other organs. As SSc progresses, patients hurt increasing difficulties with digestion, breathing, junction pain and often develop pulmonary high blood pressure. Median survival from diagnosing is eleven years (Mayes, 2004). There are about 80,000 SSc patients in the U.S. with similar numbers in the European Union. No therapies are soon available to treat the underlying movement of the disease.



About arGentis




arGentis Pharmaceuticals, LLC is a diversified specialty biopharmaceutical company seeking to license and commercialize therapies with demonstrated proof of concept for chronic diseases. Our line consists of mid- and late-stage program technologies in both autoimmunity and ophthalmology. ARG201, the company's lead compound for the treatment of systemic sclerosis, volition enter Phase III trials in 2009. The ophthalmology pipeline includes three therapies for dry eye syndrome which are uniquely applied to the outer amphetamine and lower eyelids for transdermal speech to the affected glands.



arGentis Pharmaceuticals, LLC



More information

Thursday 3 July 2008

90210 spinoff gets another star

Actress Jessica Stroup has become the newest cast member of the planned 'Beverly Hills, 90210' spin-off series.
The Hollywood Reporter says that Stroup will play Silver, the classmate of Annie (Shenae Grimes) in the pilot episode.
She makes an Internet video series called 'Answers to Life's Inane Questions Answered by a 15-Year-Old in a Bikini'.
Twenty-one-year-old Stroup will be seen on Irish cinema screens in the horror 'Prom Night'; it opens on Friday 6 June.

Ian McKellan: Lord of the Twinks

Holy Shire! Don't tell Frodo, but Gandalf the WHITE went for a dip with his very own hobbit!
Sir Ian McKellan
With nips erect, 69-year-old Sir Ian McKellan attempted to sun his bloodless, porcelain skin while cooling off in the Mediterranean with a young pal. X-men united!






See Also

Sister Of NBC Sting Suicide Victim Settles Lawsuit

NBC has settled a $105-million lawsuit brought by the sister of Louis Conradt, a Texas assistant county prosecutor who shot and killed himself when police arrived at his house as part of a Dateline "To Catch a Predator" sting in November 2006. An attorney for Patricia Conradt and an NBC News spokeswoman told today's (Wednesday) Los Angeles Times that the lawsuit had been "amicably resolved." Last February, U.S. District Judge Denny Chin rejected NBC's effort to throw out the case, saying that the network had "placed itself squarely in the middle of a police operation, pushing the police to engage in tactics that were unnecessary and unwise, solely to generate more dramatic footage for a television show. A reasonable jury could find that by doing so, NBC created a substantial risk of suicide or other harm, and that it engaged in conduct so outrageous and extreme that no civilized society should tolerate it."


See Also